Vasculogenic, Diabetic, and Neurogenic ED
The major organic ED subtypes
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- N/A (disease classification)
Reference only. Not medical advice.
What can go wrong
These subtypes are markers of serious systemic disease: vasculogenic ED signals generalized atherosclerosis; diabetic ED signals poor glycemic control and microvascular complications. Treating the erection without addressing the diabetes or vascular disease leaves the underlying threat in place.
This is something to take to a clinician. The Atlas can tell you what is known about vasculogenic, diabetic, and neurogenic ed in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The organic ED subtypes account for the majority of clinical cases. Vasculogenic ED (~70%) stems from arterial insufficiency or venous leak and is the dominant form. Diabetic ED combines microvascular disease and autonomic neuropathy, is more severe and earlier-onset, and is often less responsive to oral agents. Neurogenic ED follows spinal cord injury, multiple sclerosis, or post-prostatectomy nerve damage. Recognizing the subtype guides both treatment and the search for underlying systemic disease.
Most ED is organic, arteries, nerves, and blood sugar.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Vasculogenic ED reflects atherosclerotic narrowing of the cavernous arteries or inability to compress the emissary veins (venous leak). Diabetic ED adds endothelial dysfunction, reduced nitric oxide bioavailability, and autonomic nerve damage. Neurogenic ED interrupts the parasympathetic erectile signal at the spinal, cavernous-nerve, or cortical level.
What people get wrong
Often saidED is a local penis problem
ActuallyOrganic ED is usually a window onto systemic disease, atherosclerosis, diabetes, or neurologic injury. The penis is the messenger, not the disease.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Vasculogenic share
- ~70% of ED
- Diabetes
- Microvascular + autonomic neuropathy
- Neurogenic causes
- SCI, MS, prostatectomy
- Venous leak
- Failure of veno-occlusive mechanism
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Vasculogenic, Diabetic, and Neurogenic ED. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.